期刊文献+

辛伐他汀治疗老年高脂血症疗效及安全性研究 被引量:3

Efficacy and safety of Simvastatin Treatment in the Old Patient with Hyperlipemia
暂未订购
导出
摘要 目的:观察辛伐他汀治疗高脂血症的疗效和安全性。方法:老年高脂血症患者47例,观察治疗前后血脂变化和相关不良反应。结果:治疗30天、60天后血清总胆固醇(TC)、甘油三酯(TG)均较治疗前显著下降(P<0.01),高密度脂蛋白胆固醇(HDL-C)水平较治疗前显著升高(P<0.01);治疗前后低密度脂蛋白胆固醇(LDL-C)水平比较差异无统计学意义(P>0.05)。治疗后未出现严重不良反应。治疗后患者血糖及肌酐水平较前降低(P<0.01),结论:辛伐他汀治疗高脂血症疗效好,不良反应少,值得在临床推广应用,对患者空腹血糖及肌酐水平的影响还有待进一步研究。 Objecc: Observing the efficacy and safety of Simvastatin treatment in patient with hyperlipemia Method: observing the change of blood fat and the pre-and post-treatment related adverse reactions in 47 cases of the old patient with hyperlipemia,Result: the TC and TG After 30 days,60 days were higher than befor treatment(P〈0.01),HDL-C was higher than before treatment(P〉0.05);it was not statistic significance between the pre-and after-treatment LDC-C(P〉0.05);there was not the sever adverse reactions after treatment.The blood glucose and creatinine in patients were lower than before treatment(P〈0.01);Conclusion: There was good efficacy of Simvastatin in hyperlipemia,which was little adverse reactions,and worthy of popularization and application,whose effect is worth of researching more the blood glucose and creatinine in patients with hyperlipemia.
作者 孙秀娟
出处 《江西中医学院学报》 2011年第1期38-40,共3页 Journal of Jiangxi College of Traditional Chinese Medicine
关键词 高脂血症 辛伐他汀 疗效 安全性 Hyperlipemia Simvastatin Efficacy Safety
  • 相关文献

参考文献9

二级参考文献18

  • 1李秀钧,罗梅,李军,王煜,王双,张敏,赵家伟,马凤海,邬云红,赵桂芝,张杰,周桥,傅茂.胰岛细胞与胰岛素抵抗[J].中华内分泌代谢杂志,2004,20(4). 被引量:8
  • 2李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2127
  • 3王振杰,田秀芝,李贤,陈祚,赵连成,周北凡,武阳丰,中国高胆固醇血症控制状况调查协作组.药物治疗的高胆固醇血症患者膳食治疗状况与血脂控制达标率——高胆固醇血症临床控制状况多中心协作研究[J].中华心血管病杂志,2005,33(4):372-375. 被引量:17
  • 4李红霞,满永,国汉邦,唐蔚青,夏永静,董军,王抒,李健斋.北京市部分人群血压、血糖、血脂异常的知晓率、治疗率和达标率的调查[J].北京医学,2007,29(1):57-57. 被引量:17
  • 5He J,Gu D,Reynolds K,et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China[ J]. Circulation ,2004,110(4 ) :405 - 411.
  • 6Sever PS, Dahlof B, Poulter NR, and stroke events with atorvastatin et al. Prevention of coronary in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TriM-Lipid Lowering Arm (ASCOT-LLA) : a multicentre randomised controlled trial. Lancet, 2003,361:1149-1158.
  • 7Kowala MC, Murugesan N, Tellew J, et al. Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension. J Pharmacol Exp Ther, 2004,309: 275 -284.
  • 8Ruiz-Opazo N, Hirayama K, Akimoto K, et al. Molecular characterization of a dual endothelin-1/angiotensin Ⅱ receptor. Mol Med, 1998, 4:96-108.
  • 9Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ET receptor mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol, 2005, 288 : L480-L487.
  • 10Blanco-Colio LM, Martin-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J, 2007,153:881-888.

共引文献3255

同被引文献18

引证文献3

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部